

## Covidien Completes Sale of Confluent Surgical to Integra LifeSciences

DUBLIN--(BUSINESS WIRE)--Jan. 15, 2014--[Covidien plc](#) (NYSE: COV) today announced that it has completed the sale of its Confluent Surgical product line to Integra LifeSciences Corporation for approximately \$235 million in cash. In addition, Covidien may receive up to an additional \$30 million, contingent upon the achievement of certain performance measures related to the transition of the Confluent Surgical product line to Integra.

While Covidien expects this transaction to be several cents dilutive to fiscal 2014 earnings per share, it also expects that the underlying strength of its existing businesses will offset this dilution. As a result, Covidien does not anticipate this transaction will have a material impact on its fiscal 2014 outlook.

The completion of this transaction, which was announced Oct. 28, 2013, allows Covidien to better focus resources on its global strategic priorities.

### About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. With 2013 revenue of \$10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. Please visit [www.covidien.com](http://www.covidien.com) to learn more about our business.

### Forward-Looking Statements

*Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or Company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, our ability to effectively introduce and market new products, keep pace with advances in technology and compete effectively, implementation of healthcare reform in the United States and globally, cost-containment efforts of customers, purchasing groups, third-party payors and governmental organizations, rising commodity costs, risk of cyber-attacks, intellectual property rights disputes, complex and costly regulation, including healthcare fraud and abuse regulations and the Foreign Corrupt Practices Act, recalls or safety alerts and negative publicity relating to Covidien or its products, product liability losses and other litigation liability, manufacturing or supply chain problems or disruptions, divestitures of some of our businesses or product lines, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, risks associated with doing business outside of the United States, foreign currency exchange rates, environmental liabilities and tax legislation and potential tax liabilities. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the fiscal year ended September 27, 2013, and in subsequent filings with the SEC. We disclaim any obligation to update these forward-looking statements other than as required by law.*

Source: Covidien plc

Covidien plc

John Jordan, 508-452-4891

Manager, Communications

Surgical Solutions

[john.jordan@covidien.com](mailto:john.jordan@covidien.com)

or

Marguerite Copel, 203-821-4720

Vice President, Communications

Surgical Solutions

[marguerite.copel@covidien.com](mailto:marguerite.copel@covidien.com)

or

Coleman Lannum, CFA, 508-452-4343

Vice President

Investor Relations

[cole.lannum@covidien.com](mailto:cole.lannum@covidien.com)

or

Todd Carpenter, 508-452-4363

Senior Director

Investor Relations

[todd.carpenter@covidien.com](mailto:todd.carpenter@covidien.com)

---

<https://news.medtronic.com/2014-01-15-Covidien-Completes-Sale-of-Confluent-Surgical-to-Integra-LifeSciences>